scholarly journals Image Contrast, Image Pre-Processing, and T1 Mapping Affect MRI Radiomic Feature Repeatability in Patients with Colorectal Cancer Liver Metastases

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 240
Author(s):  
Damien J. McHugh ◽  
Nuria Porta ◽  
Ross A. Little ◽  
Susan Cheung ◽  
Yvonne Watson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Intraclass Correlation ◽  
Imaging Biomarkers ◽  
Sequence Comparisons ◽  
Colorectal Cancer Liver Metastases ◽  
T1 And T2 ◽  
Non Gaussian ◽  
The Impact ◽  
T2 Weighted Images

Imaging biomarkers require technical, biological, and clinical validation to be translated into robust tools in research or clinical settings. This study contributes to the technical validation of radiomic features from magnetic resonance imaging (MRI) by evaluating the repeatability of features from four MR sequences: pre-contrast T1- and T2-weighted images, pre-contrast quantitative T1 maps (qT1), and contrast-enhanced T1-weighted images. Fifty-one patients with colorectal cancer liver metastases were scanned twice, up to 7 days apart. Repeatability was quantified using the intraclass correlation coefficient (ICC) and repeatability coefficient (RC), and the impact of non-Gaussian feature distributions and image normalisation was evaluated. Most radiomic features had non-Gaussian distributions, but Box–Cox transformations enabled ICCs and RCs to be calculated appropriately for an average of 97% of features across sequences. ICCs ranged from 0.30 to 0.99, with volume and other shape features tending to be most repeatable; volume ICC > 0.98 for all sequences. 19% of features from non-normalised images exhibited significantly different ICCs in pair-wise sequence comparisons. Normalisation tended to increase ICCs for pre-contrast T1- and T2-weighted images, and decrease ICCs for qT1 maps. RCs tended to vary more between sequences than ICCs, showing that evaluations of feature performance depend on the chosen metric. This work suggests that feature-specific repeatability, from specific combinations of MR sequence and pre-processing steps, should be evaluated to select robust radiomic features as biomarkers in specific studies. In addition, as different repeatability metrics can provide different insights into a specific feature, consideration of the appropriate metric should be taken in a study-specific context.

A single institute retrospective trial of concurrent chemotherapy with SIR-Sphere versus SIR-Sphere alone in patients with chemotherapy-resistant colorectal cancer liver metastases.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 770-770 ◽  
Author(s):  
May Thet Cho ◽  
Jonathan Kessler ◽  
John Park ◽  
Gagandeep Singh ◽  
Yi-Jen Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Disease Control ◽  
Progression Free Survival ◽  
Concurrent Chemotherapy ◽  
Colorectal Cancer Liver Metastases ◽  
Free Survival ◽  
Kaplan Meier ◽  
Grade 3 ◽  
The Impact

770 Background: The use of selective internal radiation therapy (SIRT) with SIR-Spheres in chemotherapy-resistant colorectal cancer liver metastases (CRC-L) has been associated with favorable progression free survival (PFS) and overall survival (OS) when given alone or concurrently with chemotherapy. However, no prospective studies exist for concurrent SIRT and chemotherapy (SIRT-CT) vs. SIRT alone. We conducted a single institute retrospective trial to compare the effect of SIRT-CT to SIRT alone on liver PFS in patients with CRC-L. Methods: Patients (pts) with CRC-L treated with SIR-Spheres at City of Hope between 2009 and 2014 were identified. CRL-L patients treated with SIRT-CT or with SIRT were excluded if they received, following radioembolization, any chemotherapy/targeted regimen on which they did not previously progress. This strategy was adopted to minimize the impact of post-SIRT systemic therapy bias on SIRT-CT/SIRT liver PFS outcome. Pts characteristics included demographics, liver involvement pattern, and lines of prior chemotherapy. Liver PFS, response rate, and toxicities were compared between SIRT-CT and SIRT arms. Kaplan-Meier estimation was used for PFS analysis. Results: 48 CRC-L pts were treated with SIR-spheres; 27 satisfied the post-SIR-spheres systemic treatment criteria (14 SIRT-CT, 13 SIRT) and were included on this study. Pts characteristics included: age (median = 62; range 52-80), sex (18 males), primary site (colon: 23), hepatic disease burden (23 bilobar), 5-FU resistance/intolerance (25/2), and extrahepatic disease (22). Pts characteristics were similar between treatment arms, except for median prior therapies (SIRT-CT = 3, SIRT = 2). No SIRT-CT or SIRT associated ≥ grade 3 toxicities were noted. Disease control rates were 84% (2/13 PR; 9/13 SD) and 14% (2/14 SD on the SIRT-CT and SIRT arms, respectively (p = 0.001). Median PFS in the liver was 176 days in the SIRT-CT group vs. 91 days in the SIRT group (p = 0.0006). Conclusions: In patients with 5-FU refractory CRC-L, SIRT-CT is associated with an increased disease control rate and a prolonged DFS in comparison with SIRT alone.

Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: Long-term survival results of the phase III UFT/LV study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 672-672 ◽  
Author(s):  
Kiyoshi Hasegawa ◽  
Akio Saiura ◽  
Tadatoshi Takayama ◽  
Shinichi Miyagawa ◽  
Junji Yamamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Liver Metastases ◽  
Curative Resection ◽  
Phase Iii ◽  
Control Group ◽  
Colorectal Cancer Liver Metastases ◽  
The Impact ◽  
Better Than

672 Background: Surgical resection has been accepted as the standard therapy for colorectal cancer liver metastases (CRLM), however, high recurrence incidence even after curative resection remains a severe problem. The 1st analysis of the UFT/LV trial showed that oral UFT/LV for 6 months significantly prolonged relapse-free survival (RFS) after resection for CRLM (Kobayashi A et al. ASCO 2014, Hasegawa K et al. PlosOne 2016 E-pub). To further evaluate the impact of the UFT/LV therapy on overall survival (OS), we performed the 2nd analysis under longer follow-up period, as have been scheduled by the protocol. Methods: Patients undergoing curative resection of CRLM were randomly assigned to either UFT/LV or surgery alone (control) group. In the UFT/LV group, 5 cycles of adjuvant UFT/LV (UFT 300mg/m2 and LV 75 mg/day for 28 days followed by 7 days rest in one cycle) were administered. Results: Between 2004 and 2010, a total of 180 patients were enrolled to this trial, among whom 3 patients were ineligible for analysis. Median follow-up of the 2nd analysis was 6 years. The 5y-OS rate in the UFT/LV group was 65.3%, which was slightly better than the control group (62.2%) without statistical significance. The hazard ratio for death in the UFT/LV relative to the control was 0.86 (95% confidence interval: 0.54-1.38, P = 0.54). The OS curves of the 2 groups were identical within 4 years after resection, however, the OS curve of the UFT/LV group seemed to go higher than the control group. The 5y-RFS rate in the UFT/LV group was 36.2%, which was significantly better than that in the control group (32.3%), as have been shown by the 1st analysis. Conclusions: The results of the 2nd analysis suggested that oral UFT/LV adjuvant chemotherapy might be also useful to prolong OS, as have been confirmed for RFS. This regimen can be recommended as an alternative choice after hepatic resection for CRLM. Clinical trial information: C000000013.

scholarly journals The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0173933 ◽  
Author(s):  
Armin Wiegering ◽  
Johannes Riegel ◽  
Johanna Wagner ◽  
Volker Kunzmann ◽  
Johannes Baur ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Pulmonary Metastasectomy ◽  
Colorectal Cancer Liver Metastases ◽  
The Impact

scholarly journals Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Reem D. Mahmood ◽  
Danielle Shaw ◽  
Tine Descamps ◽  
Cong Zhou ◽  
Robert D. Morgan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Metastatic Colorectal Cancer ◽  
Targeted Therapies ◽  
Progression Free Survival ◽  
Cytotoxic Chemotherapy ◽  
Imaging Biomarker ◽  
Imaging Biomarkers ◽  
Pre Treatment ◽  
The Impact

Abstract Background Patients with metastatic colorectal cancer are treated with cytotoxic chemotherapy supplemented by molecularly targeted therapies. There is a critical need to define biomarkers that can optimise the use of these therapies to maximise efficacy and avoid unnecessary toxicity. However, it is important to first define the changes in potential biomarkers following cytotoxic chemotherapy alone. This study reports the impact of standard cytotoxic chemotherapy across a range of circulating and imaging biomarkers. Methods A single-centre, prospective, biomarker-driven study. Eligible patients included those diagnosed with colorectal cancer with liver metastases that were planned to receive first line oxaliplatin plus 5-fluorouracil or capecitabine. Patients underwent paired blood sampling and magnetic resonance imaging (MRI), and biomarkers were associated with progression-free survival (PFS) and overall survival (OS). Results Twenty patients were recruited to the study. Data showed that chemotherapy significantly reduced the number of circulating tumour cells as well as the circulating concentrations of Ang1, Ang2, VEGF-A, VEGF-C and VEGF-D from pre-treatment to cycle 2 day 2. The changes in circulating concentrations were not associated with PFS or OS. On average, the MRI perfusion/permeability parameter, Ktrans, increased in response to cytotoxic chemotherapy from pre-treatment to cycle 2 day 2 and this increase was associated with worse OS (HR 1.099, 95%CI 1.01–1.20, p = 0.025). Conclusions In patients diagnosed with colorectal cancer with liver metastases, treatment with standard chemotherapy changes cell- and protein-based biomarkers, although these changes are not associated with survival outcomes. In contrast, the imaging biomarker, Ktrans, offers promise to direct molecularly targeted therapies such as anti-angiogenic agents.

scholarly journals Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

2020 ◽  
Author(s):  
Reem Mahmood ◽  
Danielle Shaw ◽  
Tine Descamps ◽  
Cong Zhou ◽  
Robert D. Morgan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Metastatic Colorectal Cancer ◽  
Targeted Therapies ◽  
Cytotoxic Chemotherapy ◽  
Imaging Biomarker ◽  
Imaging Biomarkers ◽  
Study Results ◽  
Pre Treatment ◽  
The Impact

Abstract Background: Patients with metastatic colorectal cancer are treated with cytotoxic chemotherapy supplemented by molecularly targeted therapies. There is a critical need to define biomarkers that can optimise the use of these therapies to maximise efficacy and avoid unnecessary toxicity. However, it is important to firstly define the changes in potential biomarkers following cytotoxic chemotherapy alone. This study reports the impact of standard cytotoxic chemotherapy across a range of circulating and imaging biomarkers.Methods: A single-centre, prospective, biomarker-driven study. Eligible patients included those diagnosed with colorectal cancer with liver metastases that were planned to receive first line oxaliplatin plus 5-fluorouracil or capecitabine. Patients underwent paired blood sampling and magnetic resonance imaging (MRI), and biomarkers were associated with progression-free survival (PFS) and overall survival (OS).Results: 20 patients were recruited to the study. Results showed that chemotherapy significantly reduced the number of circulating tumour cells as well as the circulating concentrations of Ang1, Ang2, VEGF-A, VEGF-C and VEGF-D from pre-treatment to cycle 2 day 2. The changes in circulating concentrations were not associated with PFS or OS. Across all patients, the MRI perfusion parameter, Ktrans, increased in response to cytotoxic chemotherapy from pre-treatment to cycle 2 day 2 and this increase was associated with worse OS (HR 1.099, 95%CI 1.01-1.20, p=0.025).Conclusions: In patients diagnosed with colorectal cancer with liver metastases, treatment with standard chemotherapy changes cell- and protein-based biomarkers, although these changes are not associated with survival outcomes. In contrast, the imaging biomarker, Ktrans, offers promise to direct molecular targeted therapies such as anti-angiogenic agents.

scholarly journals The impact of liver MDT assessment in patients with colorectal cancer liver metastases – A population-based study

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e825
Author(s):  
E. Jonas ◽  
J. Engstrand ◽  
H. Nilsson ◽  
M. Broberg ◽  
C. Strömberg ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Population Based ◽  
Colorectal Cancer Liver Metastases ◽  
Population Based Study ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document